Therapy News and Research

RSS

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

At the 2013 American Society of Hematology meeting in Dec. 2013, James Kochenderfer, M.D., investigator in the Experimental Transplantation and Immunology Branch, NCI, presented findings from two clinical trials evaluating the use of genetically modified immune system T cells as cancer therapy.

12 Dec 2013

Research paper provides first evidence-based recommendations for using PRP in orthopaedic care

Platelet-rich plasma (PRP) has grabbed headlines in recent years for its role in helping some of sports' biggest stars return to play following injury -including golfer Tiger Woods, Super Bowl winner Hines Ward and NBA legend Kobe Bryant.

12 Dec 2013

Understanding long-term clinical stability in hemophilia patients living with HIV

People with the genetic blood clotting disorder hemophilia who have been infected with HIV for decades have an increased proportion of immune cells in their blood that specifically target HIV. This protective immune response helps chronically infected hemophilia patients survive, even during periods of HIV activity, according to a study published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

12 Dec 2013

Findings may help clinicians determine which hospitalized children at greatest risk of VTE

Life-threatening blood clots occur so rarely in children that the condition, known as venous thromboembolism (VTE), is often not on pediatricians' mental radar screens - an absence that can lead to woefully delayed recognition and treatment.

12 Dec 2013

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a National Institutes of Health-supported randomized controlled clinical trial.

12 Dec 2013

Medivir initiates phase IIa trial to evaluate efficacy of simeprevir combination therapy in HCV-infected patients

Medivir AB (STO:MVIR-B) (OMX: MVIR), announces the initiation of a phase IIa trial in chronic genotype 1 hepatitis C infected patients to evaluate the efficacy, safety and tolerability of a 12-week combination therapy of simeprevir, TMC647055 and JNJ56914845, a NS5A replication complex inhibitor.

12 Dec 2013

Researchers discover new mechanism in brain which controls tics in children with TS

A mechanism in the brain which controls tics in children with Tourette Syndrome (TS) has been discovered by scientists at The University of Nottingham.

12 Dec 2013

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

Researchers at the Icahn School of Medicine at Mount Sinai reported that a virulent new strain of influenza - the virus that causes the flu - appears to retain its ability to cause serious disease in humans even after it develops resistance to antiviral medications. The finding was included in a study that was published today in the journal Nature Communications.

12 Dec 2013

Queen's University to lead €6 million European study to find new treatments for bowel cancer

Queen's University has announced it is to lead a -6 million European study to find new treatments for bowel cancer.

12 Dec 2013

New mechanism explains why anti-tumor activity of specific immune suppressed during tumor growth

The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response.

12 Dec 2013

Scientists explore mechanisms of viruses' shells

Viruses are like small vessels containing an active component, the genetic material, that can infect a host cell. The vessel, called capsid or vector, is basically a shell that changes its shape when it penetrates a cell to infect it, and may even break into pieces.

12 Dec 2013

HCV antiviral therapy also improves diabetes outcomes

Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus improves kidney and cardiovascular outcomes for patients with diabetes. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that incidences of kidney disease, stroke, and heart attack were lower in patients treated with pegylated interferon and ribavirin compared to HCV patients not treated with antivirals or diabetic patients not infected with the virus.

12 Dec 2013

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

AstraZeneca and Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy (LD).

12 Dec 2013

Dietary amino acids improve sleep disturbances caused by brain injuries in animals

Scientists who fed a cocktail of key amino acids to mice improved sleep disturbances caused by brain injuries in the animals. These new findings suggest a potential dietary treatment for millions of people affected by traumatic brain injury (TBI)—a condition that is currently untreatable.

12 Dec 2013

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium.

12 Dec 2013

Study finds that people with COPD twice likely to develop mild cognitive impairment, memory loss

A recent Mayo Clinic study found that people with chronic obstructive pulmonary disease (COPD) are about twice as likely to develop mild cognitive impairment (MCI) -- and chances are that it will include memory loss. The study was recently published in Mayo Clinic Proceedings.

12 Dec 2013

New web-based tool developed to aid health professionals determine right treatment for injured workers

University of Alberta researchers have developed a new web-based tool to aid health professionals in determining the right treatment course for injured workers, helping them feel better and get back to work earlier.

12 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

Researchers awarded $25 million NIH grant to study critical limb ischemia treatment

A team of researchers from Brigham and Women's Hospital, Boston Medical Center and Massachusetts General Hospital has been awarded $25 million by the National Institutes of Health to conduct a four-year, randomized clinical trial-the BEST-CLI Trial (Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia). The trial will compare traditional bypass surgery with the less invasive alternative of endovascular treatment for patients with critical limb ischemia.

11 Dec 2013

Therapy News and Research

New reports demonstrate the effectiveness of modified T cells in treating blood-borne cancers

Research paper provides first evidence-based recommendations for using PRP in orthopaedic care

Understanding long-term clinical stability in hemophilia patients living with HIV

Findings may help clinicians determine which hospitalized children at greatest risk of VTE

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Medivir initiates phase IIa trial to evaluate efficacy of simeprevir combination therapy in HCV-infected patients

Researchers discover new mechanism in brain which controls tics in children with TS

New drug-resistant strain of bird flu appears to retain ability to cause serious disease in humans

Queen's University to lead €6 million European study to find new treatments for bowel cancer

New mechanism explains why anti-tumor activity of specific immune suppressed during tumor growth

Scientists explore mechanisms of viruses' shells

HCV antiviral therapy also improves diabetes outcomes

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

Dietary amino acids improve sleep disturbances caused by brain injuries in animals

Women with HER2+ breast tumors who receive combination therapy unlikely to have cancer recur

Study finds that people with COPD twice likely to develop mild cognitive impairment, memory loss

New web-based tool developed to aid health professionals determine right treatment for injured workers

New drug combination therapy effective for patients with HER2-positive breast cancer

Researchers awarded $25 million NIH grant to study critical limb ischemia treatment

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News